Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 142 (6) , 1992-1994
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2018
- The role and relevance of mast cells in urticariaImmunological Reviews, 2018
- Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patientsAllergology International, 2018
- Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skinTheranostics, 2017
- Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessmentBritish Journal of Dermatology, 2015
- Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudyJournal of Investigative Dermatology, 2015
- Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysisJournal of Dermatological Science, 2014
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013